- |||||||||| Lumigan (bimatoprost) / Senju, Allergan
Clinical, Journal: A prospective right-left comparative study to evaluate the efficacy and tolerability of combination of NB-UVB and topical bimatoprost 0.03% eye drops versus NB-UVB given alone in patients of vitiligo vulgaris. (Pubmed Central) - Nov 19, 2019
The treatment of vitiligo has been a tough challenge for dermatologists. Phototherapy, apart from being first line monotherapy,has also been used in combination with topical therapies like corticosteroids, khellin, phenylalanine, calcineurin inhibitors etc, with the aim of hastening and enhancing repigmentation and reducing side-effects.Recent reports have highlighted darkening of iris, and eyelash and periocular hyperpigmentation induced by latanoprost (prostaglandin F2α analogue) used for treatment of glaucoma.Extrapolating these findings in treatment of vitiligo, we assessed the outcome of NB- UVB and topical bimatoprost 0.03% combination versus NB-UVB alone in a prospective right-left comparative study.
- |||||||||| Lumigan (bimatoprost) / Senju, Allergan, Zioptan (tafluprost) / Santen, Merck (MSD)
Journal: Prostaglandin receptor agonists as antiglaucoma agents (a patent review 2013 - 2018). (Pubmed Central) - Nov 10, 2019
Expert opinion: To date, there has been a growing awareness over recent years of the therapeutic use of novel derivatives as new antiglaucoma pharmaceutical products. Patents involving in discover new approaches and new molecules for the treatment of glaucoma diseases encouraged the scientific community to increase the variety of drugs available for the treatment of ocular diseases.
- |||||||||| Lumigan (bimatoprost) / Senju, AbbVie, Zioptan (tafluprost) / Santen, Merck (MSD)
Enrollment closed, Surgery: CMO: RCT to Investigate if Prostaglandin Analogue Drops Increase the Risk of Cystoid Macular Oedema After Cataract Surgery. (clinicaltrials.gov) - Nov 8, 2019
P2, N=56, Active, not recruiting,
Patents involving in discover new approaches and new molecules for the treatment of glaucoma diseases encouraged the scientific community to increase the variety of drugs available for the treatment of ocular diseases. Recruiting --> Active, not recruiting
- |||||||||| Lumigan (bimatoprost) / Senju, AbbVie
Phase classification, Enrollment change: The Effects of the Water Drinking Test on Intraocular Pressure (clinicaltrials.gov) - Sep 11, 2019
P=N/A, N=23, Completed,
Trial completion date: Nov 2019 --> Sep 2020 | Trial primary completion date: Nov 2019 --> Sep 2020 Phase classification: P3 --> P=N/A | N=40 --> 23
- |||||||||| Lumigan (bimatoprost) / Senju, Allergan
Clinical, Journal: Safety data on in situ gelling bimatoprost loaded nanovesicular formulations. (Pubmed Central) - Sep 6, 2019
The in vivo ocular toxicity was performed only after confirming dermal safety, as required by OECD. Histological evaluation of various ocular tissues, following sub-conjunctival implantation with BMT-NV-IM, was done for ocular tolerance studies.
- |||||||||| Azopt (brinzolamide ophthalmic suspension 1%) / Novartis, Lumigan (bimatoprost) / Senju, Allergan, Vyzulta (latanoprostene bunod) / Bausch Health, Nicox
Effectiveness of Latanoprostene Bunod in Treating OAG and OHT: Network Meta-analysis (Moscone Center EPOSTER & VIDEO TERMINALS) - Sep 5, 2019 - Abstract #AAO2019AAO_2276;
Bimatoprost 0.03% (not used in Canada) was ranked first (SUCRA = 94%), followed by LBN (88%) and bimatoprost 0.01% (83%). Conclusion LBN numerically outranked the three most widely used PGAs, namely latanoprost, travoprost and bimatoprost 0.01%, in IOP reduction.
- |||||||||| Lumigan (bimatoprost) / Senju, Allergan
Temporal Myopic Shift Following Instillation of Bimatoprost Ophthalmic Solution (Moscone Center EPOSTER & VIDEO TERMINALS) - Sep 5, 2019 - Abstract #AAO2019AAO_2041;
Conclusion LBN numerically outranked the three most widely used PGAs, namely latanoprost, travoprost and bimatoprost 0.01%, in IOP reduction. BM induces a myopic shift and could potentially decrease NAP.
- |||||||||| Lumigan (bimatoprost) / Senju, Allergan
Retrospective data, Journal: Efficacy and safety of prostaglandin analogues in primary open-angle glaucoma or ocular hypertension patients: A meta-analysis. (Pubmed Central) - Aug 15, 2019
Bimatoprost can be used as monotherapy if another hypotensive drug in monotherapy is insufficient for IOP compensation. 03% bimatoprost appears more effective following long time use (3 and 6 month post-treatment) for IOP control compared to 0.005% latanoprost, and is more effective compared to 0.004% travoprost after being used for a certain period of time (3 months post-treatment); nevertheless, 0.005% latanoprost is better tolerated in patients with POAG or OHT.
- |||||||||| Lumigan (bimatoprost) / Senju, AbbVie
Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date: A Comparative Study of SPARC's SDP-133 Once Daily and Lumigan in Subjects With Open Angle Glaucoma or Ocular Hypertension (clinicaltrials.gov) - Jul 28, 2019
P3, N=0, Withdrawn,
In conclusion, to potentially maximize the stimulation of hair growth, laser assisted drug delivery of platelet-rich plasma - with or without bimatoprost and/or minoxidil - should be considered in patients with androgenetic alopecia in order to effectively deliver the agents to the dermis where the bulge area of the hair follicles is located. N=538 --> 0 | Trial completion date: Jul 2020 --> Jul 2019 | Not yet recruiting --> Withdrawn | Trial primary completion date: May 2020 --> Jul 2019
- |||||||||| Lumigan (bimatoprost) / Senju
Clinical, Journal: Periorbital Changes associated with Topical Prostaglandins Analogues in a Hispanic Population. (Pubmed Central) - Jul 13, 2019
N=538 --> 0 | Trial completion date: Jul 2020 --> Jul 2019 | Not yet recruiting --> Withdrawn | Trial primary completion date: May 2020 --> Jul 2019 QOL questionnaire showed that Bimatoprost side effects had the most negative impact in QOL, followed by the Latanoprost and Travoprost groups.
- |||||||||| Lumigan (bimatoprost) / Senju, AbbVie, NN1213 / Novo Nordisk
Trial completion date, Trial primary completion date: STOP-RGCD: Stop Retinal Ganglion Cell Dysfunction Study (clinicaltrials.gov) - Jun 17, 2019
P3, N=500, Recruiting,
QOL questionnaire showed that Bimatoprost side effects had the most negative impact in QOL, followed by the Latanoprost and Travoprost groups. Trial completion date: Jul 2019 --> Jul 2024 | Trial primary completion date: Jul 2019 --> Jul 2024
- |||||||||| Lumigan (bimatoprost) / Senju, AbbVie, NN1213 / Novo Nordisk
Enrollment change, Trial completion date, Trial termination: Primary Glaucoma Treatment Trial in Kenya and South Africa - SLT vs. Medication (clinicaltrials.gov) - May 2, 2019
P=N/A, N=15, Terminated,
Our results suggest a potential future application of prostaglandin analogues in the treatment of TAO. N=400 --> 15 | Trial completion date: Jan 2020 --> Jan 2019 | Recruiting --> Terminated; Unable to maintain a functional laser in the environment
- |||||||||| Lumigan (bimatoprost) / Senju
Journal: Nanofluidic microsystem for sustained intraocular delivery of therapeutics. (Pubmed Central) - Apr 30, 2019
In this proof of concept study, we constructed an anatomically similar in silico human eye model to simulate DEX release from our implant and gain insight into intraocular pharmacokinetics profile. Overall, our drug-agnostic intraocular implant represents a potentially viable platform for long-term treatment of various chronic ophthalmologic diseases, including diabetic macular edema and uveitis.
- |||||||||| Lumigan (bimatoprost) / Senju, AbbVie
Enrollment closed, Trial completion date, Trial primary completion date: Topical Bimatoprost in the Treatment of Migraine (clinicaltrials.gov) - Apr 26, 2019
P2a, N=70, Active, not recruiting,
Overall, our drug-agnostic intraocular implant represents a potentially viable platform for long-term treatment of various chronic ophthalmologic diseases, including diabetic macular edema and uveitis. Recruiting --> Active, not recruiting | Trial completion date: Dec 2018 --> Jun 2019 | Trial primary completion date: Dec 2018 --> Apr 2019
- |||||||||| Lumigan (bimatoprost) / Senju, AbbVie, Zioptan (tafluprost) / Santen, Merck (MSD)
Trial completion date, Trial primary completion date, Surgery: CMO: RCT to Investigate if Prostaglandin Analogue Drops Increase the Risk of Cystoid Macular Oedema After Cataract Surgery. (clinicaltrials.gov) - Mar 22, 2019
P2, N=60, Recruiting,
An in vivo model involving coupled mass transport in the lens and post-lens tear film (POLTF) domains predicts >50% corneal bioavailability of bimatoprost delivered via modified lenses. Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Dec 2018 --> Dec 2019
- |||||||||| Lumigan (bimatoprost) / Senju, AbbVie
Trial primary completion date: Topical Bimatoprost in the Treatment of Migraine (clinicaltrials.gov) - Aug 15, 2018
P2a, N=80, Recruiting,
Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Dec 2018 --> Dec 2019 Trial primary completion date: Jul 2018 --> Dec 2018
- |||||||||| Lumigan (bimatoprost) / Senju, AbbVie
Trial completion: Safety and Patient Satisfaction With GLASH VISTA (clinicaltrials.gov) - Aug 14, 2018
P=N/A, N=1699, Completed,
Trial primary completion date: Jul 2018 --> Dec 2018 Active, not recruiting --> Completed
- |||||||||| Lumigan (bimatoprost) / Senju, AbbVie
Trial completion: Safety of GANFORT (clinicaltrials.gov) - Jul 5, 2018
P4, N=750, Completed,
Trial completion date: Apr 2019 --> Nov 2019 | Trial primary completion date: Apr 2019 --> Nov 2019 Active, not recruiting --> Completed
- |||||||||| Simbrinza (brinzolamide/brimonidine tartrate ophthalmic suspension) / Novartis
Trial completion: SIMBRINZA (clinicaltrials.gov) - Mar 1, 2018
P4, N=289, Completed,
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||||||||| Lumigan (bimatoprost) / Senju, AbbVie
Enrollment closed, Trial primary completion date: Safety of GANFORT (clinicaltrials.gov) - Jan 26, 2018
P4, N=750, Active, not recruiting,
Recruiting --> Completed | N=20 --> 10 | Trial primary completion date: Dec 2015 --> May 2017 Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2018 --> Jun 2018
- |||||||||| Lumigan (bimatoprost) / Senju, AbbVie, Zioptan (tafluprost) / Santen, Merck (MSD)
Enrollment change, Trial initiation date, Trial primary completion date: The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients. (clinicaltrials.gov) - Jan 16, 2018
P4, N=0, Withdrawn,
Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2018 --> Jun 2018 N=30 --> 0 | Initiation date: Aug 2013 --> Jun 2014 | Trial primary completion date: Aug 2015 --> Dec 2016
- |||||||||| Simbrinza (brinzolamide/brimonidine tartrate ophthalmic suspension) / Novartis
Enrollment closed: SIMBRINZA (clinicaltrials.gov) - Jan 5, 2018
P4, N=289, Active, not recruiting,
N=30 --> 0 | Initiation date: Aug 2013 --> Jun 2014 | Trial primary completion date: Aug 2015 --> Dec 2016 Recruiting --> Active, not recruiting
- |||||||||| Lumigan (bimatoprost) / Senju, AbbVie
Enrollment closed: Safety and Patient Satisfaction With GLASH VISTA (clinicaltrials.gov) - Jul 26, 2017
P=N/A, N=1704, Active, not recruiting,
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- |||||||||| Lumigan (bimatoprost) / Senju, AbbVie
Enrollment closed: Topical Bimatoprost for Chemical Blepharoplasty (clinicaltrials.gov) - May 2, 2017
P, N=14, Active, not recruiting,
Trial primary completion date: Jun 2017 --> Jun 2018 Recruiting --> Active, not recruiting
- |||||||||| Lumigan (bimatoprost) / Senju, AbbVie
Trial primary completion date: Safety of GANFORT (clinicaltrials.gov) - Mar 17, 2017
P4, N=750, Recruiting,
Recruiting --> Active, not recruiting Trial primary completion date: Sep 2018 --> Mar 2018
|
